Vaccines Against Tuberculosis: Problems and Prospects (Review)

Nadolinskaia, Nonna I.; Карпов, Д. С.; Гончаренко, А. В.

doi:10.1134/s0003683820050129

Cited by 8 publications

(6 citation statements)

References 93 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Protein factors secreted by ESX‐1 in Mycobacterium tuberculosis induce lysis of the phagosome membrane in macrophages and interact with different cytoplasmic proteins, subverting their normal protective activities, being thus required for its virulence (Wong, 2017 ). Actually, the BCG vaccine has a defective ESX‐1 secretion system, losing most of its pathogenicity (Nadolinskaia et al, 2020 ). The ESX‐1 gene cluster of M. hassiacum (Figure 2A ) encodes homologues to some of these virulence‐related protein effectors like the EsxA/B porin‐forming proteins or the EspE and EspF proteins, whose actual roles in virulence in Mycobacterium tuberculosis are not well understood (Chirakos et al, 2020 ).…”

Section: Resultsmentioning

confidence: 99%

“…Actually, the BCG vaccine has a defective ESX-1 secretion system, losing most of its pathogenicity (Nadolinskaia et al, 2020). The ESX-1 gene cluster of M. hassiacum (Figure 2A) encodes homologues to some of these virulence-related protein effectors like the EsxA/B porin-forming proteins or the EspE and EspF proteins, whose actual roles in virulence in Mycobacterium tuberculosis are not well understood (Chirakos et al, 2020).…”

Section: Presence Of Esx Systems In M Hassiacummentioning

confidence: 99%

See 1 more Smart Citation

From accurate genome sequence to biotechnological application: The thermophile Mycolicibacterium hassiacum as experimental model

Sánchez-Costa

Gola

Rodríguez‐Sáiz³

et al. 2023

Microbial Biotechnology

View full text Add to dashboard Cite

Mycobacteria constitute a large group of microorganisms belonging to the phylum Actinobacteria encompassing some of the most relevant pathogenic bacteria and many saprophytic isolates that share a unique and complex cell envelope. Also unique to this group is the extensive capability to use and synthesize sterols, a class of molecules that include active signalling compounds of pharmaceutical use. However, few mycobacterial species and strains have been established as laboratory models to date, Mycolicibacterium smegmatis mc2155 being the most common one. In this work, we focus on the use of a thermophilic mycobacterium, Mycolicibacterium hassiacum, which grows optimally above 50°C, as an emerging experimental model valid to extend our general knowledge of mycobacterial biology as well as for application purposes. To that end, accurate genomic sequences are key for gene mining, the study of pathogenicity or lack thereof and the potential for gene transfer. The combination of long‐ and short‐massive sequencing technologies is strictly necessary to remove biases caused by errors specific to long‐reads technology. By doing so in M. hassiacum, we obtained from the curated genome clues regarding the genetic manipulation potential of this microorganism from the presence of insertion sequences, CRISPR‐Cas, type VII ESX secretion systems, as well as lack of plasmids. Finally, as a proof of concept of the applicability of M. hassiacum as a laboratory and industrial model, we used this high‐quality genome of M. hassiacum to successfully knockout a gene involved in the use of phytosterols as source of carbon and energy, using an improved gene cassette for thermostable selection and a transformation protocol at high temperature.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Presence Of Esx Systems In M Hassiacummentioning

confidence: 99%

From accurate genome sequence to biotechnological application: The thermophile Mycolicibacterium hassiacum as experimental model

Sánchez-Costa

Gola

Rodríguez‐Sáiz³

et al. 2023

Microbial Biotechnology

View full text Add to dashboard Cite

show abstract

“…BCG vaccine could be typed to various number of strains (simplified typology is in according to different amount of gene IS6110 copies) [47]. Differences in data analyses might be caused by using different BCG vaccine strains in different countries -their inequality in COVID-19 protection is postulated by one commentary article [24].…”

Section: Bcg Strains and Administration Waysmentioning

confidence: 99%

impact of Bacillus Calmette-Guérin (BCG) vaccination on the course of COVID-19

Gałązka

2022

J Educ Health Sport

View full text Add to dashboard Cite

Nowadays, Bacillus Calmette-Guérin (BCG) is the most commonly used vaccine worldwide, used typically for tuberculosis but also in non-muscle invasive bladder cancer management. Basing on previously confirmed antiviral features of BCG and first statistic data reports, BCG usage in COVID-19 prevention was claimed and its potential molecular mechanism was searched. In scientific literature there was 10 publications proving several possible mechanism of BCG interaction with SARS-CoV-2 infection immune response. The most often was cross-reactivity between various BCG and SARS-CoV-2 antigens, including those crucial for their clinical effects. In most cases, those antigens linking was shown according to bioinformatical research. According to this research, the potential role of BCG in COVID-19 management should be considered as significant, at least until the clinical trials conducted nowadays will be over.

show abstract

“…In addition to the role of the whole RD1 genomic segment in protective immunity [ 172 , 173 ], the evaluations of individual RD1 proteins for vaccine development in animals have shown the potential of PE35, PPE68, ESAT6, and CFP10 in the development of new subunit vaccines for TB [ 174 , 175 , 176 , 177 , 178 , 179 , 180 , 181 ]. Animal experiments with recombinant (r)BCG strains expressing RD1 antigens have shown the induction of protective type immune responses and protected the immunized animals after challenges with M. tuberculosis [ 182 , 183 , 184 , 185 , 186 ].…”

Section: Rd1 Genes and Encoded Proteinsmentioning

confidence: 99%

Immunological Characterization of Proteins Expressed by Genes Located in Mycobacterium tuberculosis-Specific Genomic Regions Encoding the ESAT6-like Proteins

Mustafa

2021

Vaccines

View full text Add to dashboard Cite

The 6 kDa early secreted antigen target (ESAT6) is a low molecular weight and highly immunogenic protein of Mycobacterium tuberculosis with relevance in the diagnosis of tuberculosis and subunit vaccine development. The gene encoding the ESAT6 protein is located in the M. tuberculosis-specific genomic region known as the region of difference (RD)1. There are 11 M. tuberculosis-specific RDs absent in all of the vaccine strains of BCG, and three of them (RD1, RD7, and RD9) encode immunodominant proteins. Each of these RDs has genes for a pair of ESAT6-like proteins. The immunological characterizations of all the possible proteins encoded by genes in RD1, RD7 and RD9 have shown that, besides ESAT-6 like proteins, several other proteins are major antigens useful for the development of subunit vaccines to substitute or supplement BCG. Furthermore, some of these proteins may replace the purified protein derivative of M. tuberculosis in the specific diagnosis of tuberculosis by using interferon-gamma release assays and/or tuberculin-type skin tests. At least three subunit vaccine candidates containing ESAT6-like proteins as antigen components of multimeric proteins have shown efficacy in phase 1 and phase II clinical trials in humans.

show abstract

Vaccines Against Tuberculosis: Problems and Prospects (Review)

Cited by 8 publications

References 93 publications

From accurate genome sequence to biotechnological application: The thermophile Mycolicibacterium hassiacum as experimental model

From accurate genome sequence to biotechnological application: The thermophile Mycolicibacterium hassiacum as experimental model

impact of Bacillus Calmette-Guérin (BCG) vaccination on the course of COVID-19

Immunological Characterization of Proteins Expressed by Genes Located in Mycobacterium tuberculosis-Specific Genomic Regions Encoding the ESAT6-like Proteins

Contact Info

Product

Resources

About